An observational study in Chronic Inflammatory Rheumatic Diseases, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Rheumatic Diseases with a site in France — 8 open to participants now, 8 under way, none of them phase 3. Rheumatic Diseases · France.
Among the 25 studies in Rheumatic Diseases with a site in France, this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2026, is one of 15 observational ones, and was the 24th registered.
264 studies on the registry are indexed under Rheumatic Diseases; 60 are open to participants now.
Browse Rheumatic Diseases studies →8 of the 25 studies in Rheumatic Diseases with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18–80
University Hospital, Brest · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 41 Rheumatic Diseases studies recruiting now, 18 (44%) set no upper age limit and 12 (29%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 60 is below the median of 225 across 90 observational studies indexed under Rheumatic Diseases.
Median enrollment 123 across the 10 interventional studies, 397 across the 15 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 25 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 4 studies filed under Rheumatic Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Rheumatic Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07005804Lille Catholic UniversityCalcium Pyrophosphate Deposition (CPPD) Disease | 2027-05 |
| NCT07469787Assistance Publique - Hôpitaux de ParisCompassionate Care and Organization of Healthcare Services for a Successful Transition in Rheumatology | 2027-08-26 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Rheumatic Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic inflammatory rheumatic diseases (CIRD), like all chronic somatic disease, can impair self-esteem and self-image in affected individuals. Numerous studies conducted in this population have confirmed this fact. Therapeutic patient education (TPE) programs aim to help patients acquire self-care and adaptive skills. However, there is a near-total absence of workshops specifically dedicated to self-image in TPE programs for CIRD. Such educational interventions have shown their effectiveness in contexts such as cancer and obesity. Our study aims to evaluate their effectiveness for patients with CIR.
A chronic disease is a long-term, progressive illness that affects the daily life of the person affected. The onset of the disease is a major upheaval, a moment of rupture between a before and an after. Physical functions and appearance can be altered by the disease (deformities, stiffness… in the case of rheumatic diseases) and by treatments.
According to Schilder, body image is "the way our body appears to ourselves." It can be defined as the set of perceptions, emotions, and thoughts related to appearance. It consists of perceptions but also of representations and feelings, which are built and evolve throughout the individual's experience. It is not limited to physical appearance and properties. It is the foundation of identity.
The disease affects the body, but also has an impact on self-perception, self-esteem, and even identity.
The literature highlights the importance of using qualitative research in addition to quantitative methods to grasp the full complexity of body image.
Despite the progress and effectiveness of treatments, recent studies showed that patients with chronic inflammatory rheumatic diseases (CIRD) have an unsatisfactory, disturbed body image. Literature data also reveal that self-esteem and quality of life in this population are lower than in the general population.
Most studies focused on the consequences of the disease, and very few on the actions taken to address these difficulties encountered by patients, even though such actions are recommended.
Therapeutic patient education (TPE) is support offered to the patient and their relatives so they can take ownership of their disease. TPE is a comprehensive approach that meets the patient's needs and aims to maintain and/or improve quality of life with the illness.
Most therapeutic education workshops related to self-image are proposed in the context of cancer, psychiatric disorders, or obesity. Body image is rarely the direct subject of a workshop in programs aimed at patients with CIRD.
A few studies on the impact of image consulting workshops have been conducted in oncology, but very few in the context of other diseases, including rheumatic conditions. Existing studies show an improvement in self-image, self-esteem, and quality of life after educational interventions, thus a real benefit for patients.
The target population will consist of patients with RIC (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis) participating in the ETP programme
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rosenberg Scale, SF36, MBRSQ
Semi-structured individual interviews
To evaluate a therapeutic patient education intervention focused on self-image in patients with chronic inflammatory rheumatic diseases
Multidimensional Body-Self Relations Questionnaire (MBSRQ)
Time frame: 3 months following completion of the 'self-image' module
To evaluate a therapeutic patient education intervention on each domain of self-image
Measurement of each subscale of the Multidimensional Body-Self Relations Questionnaire (MBSRQ)
Time frame: 3 months following completion of the 'self-image' module
To evaluate a therapeutic patient education intervention focused on self-image in relation to self-esteem.
Rosenberg Self-Esteem Scale before participation : min = 10, max=40
Time frame: 3 months following completion of the 'self-image' module
To evaluate a therapeutic patient education intervention focused on self-image in relation to quality of life.
Measurement of the quality of life score using the SF-36 questionnaire
Time frame: 3 months following completion of the 'self-image' module
To explore body image in patients after participating in therapeutic education workshops on self-image.
Data from individual qualitative interviews (inductive approach).
Time frame: 4 months following completion of the 'self-image' module
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Mar 2029, 33 months after the start.
Of 37 observational studies under Rheumatic Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 14. This study's planned 33 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Oct 2025 → Jun 2026, primary completion Jul 2028 → Mar 2029 and completion Oct 2028 → Jun 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →